- Home
- MIRA vs SCNX Comparison
MIRA vs SCNX Comparison
Compare MIRA & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- SCNX
- Stock Information
- Founded
- MIRA 2020
- SCNX 2010
- Country
- MIRA United States
- SCNX United States
- Employees
- MIRA N/A
- SCNX N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- MIRA Health Care
- SCNX Health Care
- Exchange
- MIRA Nasdaq
- SCNX Nasdaq
- Market Cap
- MIRA 19.5M
- SCNX 21.2M
- IPO Year
- MIRA 2023
- SCNX 2020
- Fundamental
- Price
- MIRA $1.42
- SCNX $2.12
- Analyst Decision
- MIRA Strong Buy
- SCNX
- Analyst Count
- MIRA 1
- SCNX 0
- Target Price
- MIRA $17.00
- SCNX N/A
- AVG Volume (30 Days)
- MIRA 907.1K
- SCNX 214.3K
- Earning Date
- MIRA 08-15-2025
- SCNX 08-18-2025
- Dividend Yield
- MIRA N/A
- SCNX N/A
- EPS Growth
- MIRA N/A
- SCNX N/A
- EPS
- MIRA N/A
- SCNX N/A
- Revenue
- MIRA N/A
- SCNX $146,901.00
- Revenue This Year
- MIRA N/A
- SCNX N/A
- Revenue Next Year
- MIRA N/A
- SCNX N/A
- P/E Ratio
- MIRA N/A
- SCNX N/A
- Revenue Growth
- MIRA N/A
- SCNX N/A
- 52 Week Low
- MIRA $0.73
- SCNX $0.69
- 52 Week High
- MIRA $2.70
- SCNX $10.23
- Technical
- Relative Strength Index (RSI)
- MIRA 44.28
- SCNX N/A
- Support Level
- MIRA $1.35
- SCNX N/A
- Resistance Level
- MIRA $1.77
- SCNX N/A
- Average True Range (ATR)
- MIRA 0.10
- SCNX 0.00
- MACD
- MIRA -0.05
- SCNX 0.00
- Stochastic Oscillator
- MIRA 15.56
- SCNX 0.00
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.